Methods to Improve the Therapeutic Index of Activated T Cells
OwnerGray D Shawinventor
Life of this patent
Estimating the term…
Abstract
Methods of using soluble tandem selectin glycoprotein ligand (TSGL) and TSGL fusion proteins, such as TSGL-Ig, for therapeutic treatment of cancers, including in combination with T cell activation therapies or an adoptive cell transfer (ACT) therapy.
Claims20
A method of use, comprising administering a soluble form of human PSGL-1 in combination with an adoptive cell transfer (ACT) therapy, wherein the soluble form of PSGL-1 comprises a soluble tandem selectin glycoprotein ligand (TSGL) wherein each of the PSGL-1 domains comprises amino acids 10 to 16 of SEQ ID NO:2.
A method of treating a cancer, comprising administering to a subject in need thereof a soluble form of human PSGL-1 in an amount effective to treat the cancer, wherein the soluble form of PSGL-1 comprises a soluble tandem selectin glycoprotein ligand (TSGL) wherein each of the PSGL-1 domains comprises amino acids 5 to 16 of SEQ ID NO:2.
A method of treating or preventing cytokine release syndrome (CRS), comprising administering to a subject in need thereof a soluble form of human PSGL-1 in an amount effective to reduce the elevation of VWF or Ang-2 serum concentrations, wherein the soluble form of PSGL-1 comprises a soluble tandem selectin glycoprotein ligand (TSGL) wherein each of the PSGL-1 domains comprises amino acids 10 to 16 of SEQ ID NO:2.
Dependencies are inferred from the claim text.